Literature DB >> 19939932

Inactivation of Burkholderia cepacia complex phage KS9 gp41 identifies the phage repressor and generates lytic virions.

Karlene H Lynch1, Kimberley D Seed, Paul Stothard, Jonathan J Dennis.   

Abstract

The Burkholderia cepacia complex (BCC) is made up of at least 17 species of gram-negative opportunistic bacterial pathogens that cause fatal infections in patients with cystic fibrosis and chronic granulomatous disease. KS9 (vB_BcenS_KS9), one of a number of temperate phages isolated from BCC species, is a prophage of Burkholderia pyrrocinia LMG 21824. Transmission electron micrographs indicate that KS9 belongs to the family Siphoviridae and exhibits the B1 morphotype. The 39,896-bp KS9 genome, comprised of 50 predicted genes, integrates into the 3' end of the LMG 21824 GTP cyclohydrolase II open reading frame. The KS9 genome is most similar to uncharacterized prophage elements in the genome of B. cenocepacia PC184 (vB_BcenZ_ PC184), as well as Burkholderia thailandensis phage phiE125 and Burkholderia pseudomallei phage phi1026b. Using molecular techniques, we have disrupted KS9 gene 41, which exhibits similarity to genes encoding phage repressors, producing a lytic mutant named KS9c. This phage is incapable of stable lysogeny in either LMG 21824 or B. cenocepacia strain K56-2 and rescues a Galleria mellonella infection model from experimental B. cenocepacia K56-2 infections at relatively low multiplicities of infection. These results readily demonstrate that temperate phages can be genetically engineered to lytic form and that these modified phages can be used to treat bacterial infections in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939932      PMCID: PMC2812329          DOI: 10.1128/JVI.01843-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Conserved translational frameshift in dsDNA bacteriophage tail assembly genes.

Authors:  Jun Xu; Roger W Hendrix; Robert L Duda
Journal:  Mol Cell       Date:  2004-10-08       Impact factor: 17.970

Review 2.  Role of phages in the pathogenesis of Burkholderia, or 'Where are the toxin genes in Burkholderia phages?'.

Authors:  Elizabeth J Summer; Jason J Gill; Chris Upton; Carlos F Gonzalez; Ry Young
Journal:  Curr Opin Microbiol       Date:  2007-08-23       Impact factor: 7.934

3.  Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.

Authors:  Biswajit Biswas; Sankar Adhya; Paul Washart; Brian Paul; Andrei N Trostel; Bradford Powell; Richard Carlton; Carl R Merril
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

4.  Phenol and trichloroethylene degradation by Pseudomonas cepacia G4: kinetics and interactions between substrates.

Authors:  B R Folsom; P J Chapman; P H Pritchard
Journal:  Appl Environ Microbiol       Date:  1990-05       Impact factor: 4.792

5.  A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo.

Authors:  Slade A Loutet; Ronald S Flannagan; Cora Kooi; Pamela A Sokol; Miguel A Valvano
Journal:  J Bacteriol       Date:  2006-03       Impact factor: 3.490

6.  Burkholderia thailandensis E125 harbors a temperate bacteriophage specific for Burkholderia mallei.

Authors:  Donald E Woods; Jeffrey A Jeddeloh; David L Fritz; David DeShazer
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

7.  Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex.

Authors:  Kimberley D Seed; Jonathan J Dennis
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

8.  Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system.

Authors:  Ratree Platt; Donald L Reynolds; Gregory J Phillips
Journal:  FEMS Microbiol Lett       Date:  2003-06-27       Impact factor: 2.742

9.  Biosynthesis and structure of the Burkholderia cenocepacia K56-2 lipopolysaccharide core oligosaccharide: truncation of the core oligosaccharide leads to increased binding and sensitivity to polymyxin B.

Authors:  Ximena Ortega; Alba Silipo; M Soledad Saldías; Christa C Bates; Antonio Molinaro; Miguel A Valvano
Journal:  J Biol Chem       Date:  2009-06-12       Impact factor: 5.157

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  12 in total

1.  Characterization of DC1, a broad-host-range Bcep22-like podovirus.

Authors:  Karlene H Lynch; Paul Stothard; Jonathan J Dennis
Journal:  Appl Environ Microbiol       Date:  2011-12-02       Impact factor: 4.792

2.  Genomes and characterization of phages Bcep22 and BcepIL02, founders of a novel phage type in Burkholderia cenocepacia.

Authors:  Jason J Gill; Elizabeth J Summer; William K Russell; Stephanie M Cologna; Thomas M Carlile; Alicia C Fuller; Kate Kitsopoulos; Leslie M Mebane; Brandi N Parkinson; David Sullivan; Lisa A Carmody; Carlos F Gonzalez; John J LiPuma; Ry Young
Journal:  J Bacteriol       Date:  2011-07-29       Impact factor: 3.490

3.  Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.

Authors:  Fatima Kamal; Jonathan J Dennis
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

4.  Identification and characterization of ϕH111-1: A novel myovirus with broad activity against clinical isolates of Burkholderia cenocepacia.

Authors:  Karlene H Lynch; Yongjie Liang; Leo Eberl; David S Wishart; Jonathan J Dennis
Journal:  Bacteriophage       Date:  2013-10-01

5.  Comparative analysis of two phenotypically-similar but genomically-distinct Burkholderia cenocepacia-specific bacteriophages.

Authors:  Karlene H Lynch; Paul Stothard; Jonathan J Dennis
Journal:  BMC Genomics       Date:  2012-06-07       Impact factor: 3.969

6.  Genomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex.

Authors:  Karlene H Lynch; Paul Stothard; Jonathan J Dennis
Journal:  BMC Genomics       Date:  2010-10-25       Impact factor: 3.969

Review 7.  The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Karlene H Lynch; Jonathan J Dennis
Journal:  Front Cell Infect Microbiol       Date:  2012-01-20       Impact factor: 5.293

8.  Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia.

Authors:  Karlene H Lynch; Ashraf H Abdu; Max Schobert; Jonathan J Dennis
Journal:  BMC Genomics       Date:  2013-08-27       Impact factor: 3.969

9.  Single molecule real-time sequencing of Xanthomonas oryzae genomes reveals a dynamic structure and complex TAL (transcription activator-like) effector gene relationships.

Authors:  Nicholas J Booher; Sara C D Carpenter; Robert P Sebra; Li Wang; Steven L Salzberg; Jan E Leach; Adam J Bogdanove
Journal:  Microb Genom       Date:  2015-10

10.  The isolation and characterization of two Stenotrophomonas maltophilia bacteriophages capable of cross-taxonomic order infectivity.

Authors:  Danielle L Peters; Karlene H Lynch; Paul Stothard; Jonathan J Dennis
Journal:  BMC Genomics       Date:  2015-09-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.